OPKO Health logo

OPKO Health

OPK | NASDAQ
Chart Builder DCF Calculator
$1.62
-$0.06 (-3.57%)
At close: Nov 16, 2026, 4:00 PM ET
$1.62
$0.00 (+0.05%)
After-hours: Nov 16, 2026, 7:52 PM ET
-3.57%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
33.6
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #694/1021 (Top 68%)

Key Statistics

Market Data

Market Cap $1.2B
1D Range
1.61 1.68
52W Range
1.10 1.77

Valuation (TTM)

PE -8.53
PB 1.08
EV/EBITDA -48.59

Valuation (NTM)

Forward PE N/A
Forward PEG 0.23
Price Target $3.13
Loading financial charts...

Profile

OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other inte...

Sector Healthcare
Employees 2,275
IPO Date Nov 2, 1995
Fiscal Year January - December

Latest News

What OPKO Health (OPK) Said on Its Q3 Earnings Call

12 days ago · marketbeat.com

What OPKO Health (OPK) Said on Its Q3 Earnings Call
OPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript

12 days ago · seekingalpha.com

OPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript
OPKO Health (OPK) Reports Q3 Loss, Misses Revenue Estimates

12 days ago · zacks.com

OPKO Health (OPK) Reports Q3 Loss, Misses Revenue Estimates
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results

12 days ago · globenewswire.com

OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026

20 days ago · globenewswire.com

OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026
OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly

21 days ago · globenewswire.com

OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly
OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal

1 month ago · benzinga.com

OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal

2 months ago · zacks.com

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

2 months ago · zacks.com

OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

2 months ago · marketbeat.com

OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

Earnings

Latest Earnings
Nov 4, 2026
EPS
-$0.05
Beat +26.47%
REV
$65.4M
Miss -52.13%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
2
Consensus
Buy
Price Target
$3.13
Upside
+93.21%
Buy (2)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.